Genesis Drug Discovery and Development Acquires Integrated Analytical Solutions to Add Off the Shelf PK Profiling Capabilities to Its Portfolio
News provided by
Share this article
® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD
3) announced today that it has acquired the Berkeley-based CRO Integrated Analytical Solutions (IAS). Founded in 2004 and located in the San Francisco bay area, IAS is a GxP-compliant CRO providing bioanalytical, drug metabolism, and analytical chemistry services to clients worldwide.
Integrated Analytical Solutions (IAS) Logo This is our second acquisition in the space of two months as we further expand our presence in the San Francisco bay area, which we see as a market with tremendous growth potential for drug discovery services said Eli Mordechai, Ph.D., Chief Executive Officer (CEO) of GBG. Adding IAS s GxP compliant bioanalytical platform to GD
Genesis Drug Discovery and Development Expands Its Presence in the Clinical Space by Acquiring STATKING Clinical Services
News provided by
Share this article
® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD
3) announced today that it has acquired the Cincinnati-based CRO STATKING Clinical Services. Established in 1989, STATKING provides clinical trial services, including clinical trial management, protocol development, biostatistics, clinical data management, clinical study monitoring, medical writing, medical monitoring, safety reporting, and project management for the regulatory approval of novel drug and medical device products.
STATKING Clinical Services We are very pleased to have STATKING join GBG, and this acquisition demonstrates our commitment to making GD